1. Home
  2. SSII vs CSTL Comparison

SSII vs CSTL Comparison

Compare SSII & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SS Innovations International Inc.

SSII

SS Innovations International Inc.

HOLD

Current Price

$3.75

Market Cap

716.5M

Sector

N/A

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$23.60

Market Cap

722.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSII
CSTL
Founded
N/A
2007
Country
India
United States
Employees
483
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
716.5M
722.8M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SSII
CSTL
Price
$3.75
$23.60
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$45.50
AVG Volume (30 Days)
52.5K
333.5K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
N/A
$2.42
Revenue Next Year
N/A
$12.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.66
52 Week Low
$3.11
$14.59
52 Week High
$10.00
$44.28

Technical Indicators

Market Signals
Indicator
SSII
CSTL
Relative Strength Index (RSI) 50.88 55.26
Support Level $3.29 $23.21
Resistance Level $5.14 $24.49
Average True Range (ATR) 0.35 0.96
MACD 0.04 0.10
Stochastic Oscillator 53.06 66.36

Price Performance

Historical Comparison
SSII
CSTL

About SSII SS Innovations International Inc.

SS Innovations International Inc is a commercial-stage surgical robotics company. It designs, manufactures, and markets a surgical robotic system called the SSi Mantra Surgical Robotic System (the SSi Mantra) intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac surgeries. Additionally, the company offers a suite of stapling, energy, and core instrumentation for its surgical systems, under the brand name of SSi Mudra.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: